Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study

Geraldine Dominiak-Felden, Corrado Gobbo, François Simondon

The image for Fig 1 is incorrect. Please see the correct Fig 1 here.
Fig 1. Incidence of genital warts per 100,000 individuals (dashed line: females; solid line: males) and qHPV vaccine uptake in individuals aged 16–22 years (A), 23–30 years (B), 31–40 years (C) and 41–59 years (D) affiliated to the MLOZ sick fund (Belgium) between 2006 and 2013 (standardised estimates).

doi:10.1371/journal.pone.0148665.g001

There are errors in the fourth row of Table 2. Please see the corrected Table 2 here.

Table 2. Characteristics of the vaccine effectiveness study population as a function of their vaccination status.

| Vaccination status | n     | Age* at 1st dose (years) | Age* end of study (years) | Number with GWs (%) | Age* 1st GWs episode (years) |
|--------------------|-------|--------------------------|---------------------------|---------------------|------------------------------|
| Unvaccinated       | 63    | 180                      | 20.2                      | 244 (0.39)          | 20.1                         |
| 1 dose             | 4,020 | 15.8                     | 20.1                      | 16 (0.21)           | 19.1                         |
| 2 doses            | 3,587 | 14.7                     | 19.7                      | 14 (0.04)           | 19.1                         |
| 3 doses            | 35    | 792                      | 14.7                      | 12 (0.05)           | 19.3                         |
| 3 doses (as per schedule) | 24    | 791                      | 14.7                      | 12 (0.05)           | 19.3                         |

*Median age

doi:10.1371/journal.pone.0148665.t001
There is an error in the third sentence of the last paragraph of the Results section. The correct sentence is: In this second sensitivity analysis, the GWs IR was 113.9 (95% CI: 101.3–128.1) per 100,000 person-years in the non-qHPV vaccine group vs 14.2 (95% CI: 8.8; 22.8) per 100,000 person-years among women fully vaccinated with qHPV vaccine.

Reference
1. Dominiak-Felden G, Gobbo C, Simondon F (2015) Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLoS ONE 10(7): e0132404. doi:10.1371/journal.pone.0132404 PMID: 26147096